Latest News

If you are wondering whether BGC Group at around $8.93 is a bargain or a value trap, you are not alone. That is exactly what we are going to unpack. Despite being down 0.6% over the last week and 4.3% year to date, the stock is still up 4.4% over the past month, 2.9% over the last year, and 138.9% over three years and 124.6% over five years, which naturally raises questions about what is already priced in. Recently, BGC Group has been in the spotlight for its ongoing transformation into a...

If you are wondering whether Cohen & Steers at around $63 a share is a bargain or a value trap, you are not alone. That is exactly what we are going to unpack today. The stock has bounced about 0.6% over the last week and 6.3% over the past month, but those moves follow a much steeper slide of 31.1% year to date and 28.2% over the last year. This level of volatility has put Cohen & Steers back on some value investors radars as they reassess whether institutional demand for listed real assets...

OneSpaWorld Holdings (OSW) is back in focus after its latest quarterly results met expectations and highlighted smoother operations, reinforcing market confidence as cruise oversupply worries fade and spa demand holds steady. See our latest analysis for OneSpaWorld Holdings. The latest earnings and upbeat commentary have helped the stock regain its footing, with a solid year to date share price return and a standout three year total shareholder return suggesting momentum is quietly rebuilding...

Westamerica Bancorporation (WABC) has quietly outperformed many regional peers recently, with the stock up around 9% over the past month even as annual revenue and net income both slipped. See our latest analysis for Westamerica Bancorporation. That recent 1 month share price return of 9.3% looks more like a sentiment reset than a one day blip. This is especially the case given the year to date share price return is still slightly negative and the 3 year total shareholder return sits just...

Iberdrola (BME:IBE) just deepened its partnership with Microsoft through two long term power purchase agreements totaling 150 MW, plus a new global AI solution, sharpening its positioning at the crossroads of energy and technology. See our latest analysis for Iberdrola. That deepened Microsoft partnership lands at a strong moment for Iberdrola, with the share price up a robust 32.14% year to date and a standout 43.10% total shareholder return over the past year, suggesting momentum is still...

Earlier this week, Rezolve AI said December 2025 is set to be its strongest month ever, with revenue expected to exceed US$17,000,000 even as it continues to record a GAAP net loss due to non-cash and one-time items. The company’s guidance that annual recurring revenue should surpass US$200,000,000 by year-end 2025, while targeting positive adjusted EBITDA, marks a pivotal moment in its push to scale generative AI solutions for commerce despite a still-stretched balance sheet. We’ll now...

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index closing lower due to weak trade data from China, highlighting global economic interdependencies. Despite such broader market fluctuations, penny stocks remain an intriguing area for investors seeking growth opportunities in smaller or newer companies. While the term "penny stocks" may seem outdated, these investments can still offer potential when backed by strong financial health and resilience.

The Campbell's Company's ( NASDAQ:CPB ) investors are due to receive a payment of $0.39 per share on 2nd of February...

It's been a sad week for Worthington Enterprises, Inc. ( NYSE:WOR ), who've watched their investment drop 10% to...

FORTEC Elektronik AG's ( ETR:FEV ) dividend is being reduced from last year's payment covering the same period to €0.40...

Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...

TORM (CPSE:TRMD A) has just shaken up its leadership by appointing veteran dealmaker Simon Mackenzie Smith as Chair of the Board, a move that could subtly reshape strategy, capital allocation, and investor expectations. See our latest analysis for TORM. The leadership change comes as TORM’s 30 day share price return of minus 14.42 percent and year to date share price return of minus 16.41 percent contrast with a resilient 1 year total shareholder return of 5.99 percent. This suggests short...

In December 2025, Keysight Technologies announced a five-year Master Research Collaboration Agreement with Singapore’s leading quantum research institutions, alongside new AI-powered design assistants and advanced automotive and cybersecurity demonstrations unveiled around CES 2026. Together, these moves highlight how Keysight is deepening its role in quantum computing while embedding AI across its software tools and automotive test ecosystem, reinforcing its push into higher-value,...

Arrowhead Pharmaceuticals recently dosed the first subjects in a Phase 1/2a trial of ARO-MAPT, an RNAi therapy targeting tauopathies such as Alzheimer’s disease, using a new delivery system designed to cross the blood-brain barrier after subcutaneous injection. This marks Arrowhead’s initial move into central nervous system applications of its TRiM RNAi platform, potentially broadening its reach beyond liver and cardiometabolic indications. Next, we’ll examine how Arrowhead’s first...

Earlier this month, Deutsche Bank initiated coverage on East West Bancorp, citing its cross-border U.S.–Asia franchise and steps to trim commercial real estate exposure while expanding fee-based businesses such as wealth management. At the same time, insider share sales of about US$1,442,905 and the bank’s record quarterly results added extra context to shifting investor sentiment. We’ll now examine how Deutsche Bank’s focus on East West Bancorp’s cross-border strengths could influence its...

Recently, Technology One highlighted its practice of reinvesting around a quarter of its revenue into research and development to strengthen its enterprise software for government, education, and corporate customers, while targeting expansion in large markets such as the U.K. and higher education. This emphasis on heavy R&D spending and entry into sizeable new sectors has reinforced perceptions that the company is deliberately building long-term product relevance and growth options. Next,...

Melco Resorts & Entertainment recently outlined plans to resume quarterly dividends by the end of 2026 while closing two Mocha Clubs and reallocating gaming machines across its Macau portfolio, alongside reopening the renovated Countdown Hotel by the third quarter of 2026. These moves suggest management is prioritizing shareholder returns and higher‑quality guest experiences in Macau through more focused properties and refreshed non-gaming offerings. Next, we’ll examine how the planned...

Phoenix Financial (TASE:PHOE) just unveiled a strategic partnership with Blackstone, committing up to 5 billion dollars across corporate, real estate, and asset based credit, a move that could reshape its long term earnings mix. See our latest analysis for Phoenix Financial. The move comes after a powerful run, with Phoenix Financial posting a roughly 36 percent 3 month share price return and a standout 5 year total shareholder return of about 714 percent. This suggests momentum is still very...

Recently, William Blair downgraded Kemper (KMPR) from “Market Perform” to “Underperform,” adding to a series of cautious analyst moves and reflecting a more guarded view of the insurer’s prospects. This shift contributes to a mixed but increasingly wary analyst landscape around Kemper, where a consensus “Hold” rating underscores uncertainty about the company’s path ahead. We’ll now examine how William Blair’s downgrade and the broader cautious analyst tone may affect Kemper’s existing...

Structure Therapeutics recently began a first-in-human Phase 1 trial of ACCG-2671, an oral small-molecule amylin receptor agonist for obesity, evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in both healthy volunteers and people with obesity using single- and multiple-ascending dose cohorts. This move broadens the company’s obesity franchise beyond its oral GLP-1 candidate aleniglipron, positioning Structure to pursue future combination weight-loss regimens built...

Recently, Piper Sandler Companies was highlighted as a strong small-cap name after delivering exceptional annual revenue growth, profitable incremental sales, and a stronger balance sheet over the past two years. This recognition positions the firm as a rare small-cap financial services player that has translated market share gains into meaningfully higher earnings quality. Next, we’ll explore how this profitable revenue expansion and balance sheet improvement may influence Piper Sandler’s...

Sinclair (SBGI) has quietly outpaced the broader market over the past 3 years, even as the share price slipped over the past month. This may set up an interesting entry point for patient investors. See our latest analysis for Sinclair. The recent pullback, including a 7 day share price return of negative 5.47 percent and a year to date share price return of negative 5.41 percent, contrasts with a resilient 3 year total shareholder return of 30.44 percent. This suggests longer term momentum is...